import {Ctml3} from "../support/interfaces/CtmlInterfaces3";

export const NCT03297606_CAPTUR: Ctml3 =
{
  "age": "Adult",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Olaparib"
      },
      {
        "drug_name": "Dasatinib"
      },
      {
        "drug_name": "Nivolumab plus Ipilimumab"
      },
      {
        "drug_name": "Axitinib"
      },
      {
        "drug_name": "Bosutinib"
      },
      {
        "drug_name": "Crizotinib"
      },
      {
        "drug_name": "Palbociclib"
      },
      {
        "drug_name": "Sunitinib"
      },
      {
        "drug_name": "Temsirolimus"
      },
      {
        "drug_name": "Erlotinib"
      },
      {
        "drug_name": "Trastuzumab plus Pertuzumab"
      },
      {
        "drug_name": "Vemurafenib plus Cobimetinib"
      },
      {
        "drug_name": "Vismodegib"
      }
    ]
  },
  "last_updated": "March 9, 2021",
  "long_title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "BCCA - Vancouver Cancer Centre"
      },
      {
        "is_primary": "Y",
        "management_group_name": "Cancer Centre of Southeastern Ontario at Kingston General Hospital"
      },
      {
        "is_primary": "Y",
        "management_group_name": "London Health Sciences Centre"
      },
      {
        "is_primary": "Y",
        "management_group_name": "The Ottawa Hospital Cancer Centre"
      },
      {
        "is_primary": "Y",
        "management_group_name": "Princess Margaret Cancer Centre"
      }
    ]
  },
  "match": [
    {
      "clinical": {
        "disease_status": [
          "Lymphoma, Non-Hodgkin",
          "Multiple Myeloma",
          "Advanced Solid Tumors"
        ]
      }
    }
  ],
  "nct_id": "NCT03297606",
  "nct_purpose": "Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumors that might be responsible for their malignant behavior such as uncontrolled growth and spread. Some of these changes can be druggable, i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centers and programs have initiated this type of molecular profiling across Canada, with the goal to identify druggable changes in tumors to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec for adult tumours, as well as a pan-Canadian profiling centre for pediatrics. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumor profiling by one of the above mentioned programs, and have druggable changes identified in their cancers.",
  "phase": "II",
  "prior_treatment_requirements": [
    "Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour, multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment.",
    "ECOG performance status 0-2.",
    "Patients must have normal organ function as follows: 1. Absolute neutrophil count: ≥ 1.5 x 10^9/L for solid tumours; ≥ 1.0 x 10^9/L for neurologic malignancies 2. Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma or lymphoma). 3. Total bilirubin ≤ 1.5 x UNL. 4. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be < 5 x ULN; 5. Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg/min/1.73µ^2",
    "Patients must have measurable disease",
    "Results must be available from tumour genomic or protein expression testing. The test may have been performed on the primary tumour or a metastatic deposit (including bone marrow) in a diagnostic or research laboratory and must reveal a potentially actionable variant.",
    "Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to the screening step to document their willingness to participate",
    "Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits. placed on patients being considered for this trial.",
    "Women/men of childbearing potential must have agreed to use a highly effective contraceptive method."
  ],
  "protocol_no": "PM1",
  "short_title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)",
  "site_list": {
    "site": [
      {
        "coordinating_center": "Y",
        "site_name": "BCCA - Vancouver Cancer Centre",
        "site_status": "Open to Accrual",
        "uses_cancer_center_irb": "Y"
      },
      {
        "coordinating_center": "Y",
        "site_name": "Cancer Centre of Southeastern Ontario at Kingston General Hospital",
        "site_status": "Open to Accrual",
        "uses_cancer_center_irb": "Y"
      },
      {
        "coordinating_center": "Y",
        "site_name": "London Health Sciences Centre",
        "site_status": "Open to Accrual",
        "uses_cancer_center_irb": "Y"
      },
      {
        "coordinating_center": "Y",
        "site_name": "The Ottawa Hospital Cancer Centre",
        "site_status": "Open to Accrual",
        "uses_cancer_center_irb": "Y"
      },
      {
        "coordinating_center": "Y",
        "site_name": "Princess Margaret Cancer Centre",
        "site_status": "Open to Accrual",
        "uses_cancer_center_irb": "Y"
      }
    ]
  },
  "sponsor_list": {
    "sponsor": [
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Canadian Cancer Trials Group"
      },
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "AstraZeneca"
      },
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Bristol-Myers Squibb"
      },
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Hoffmann-La Roche"
      },
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Pfizer"
      }
    ]
  },
  "staff_list": {
    "protocol_staff": [
      {
        "email_address": "Lillian.Siu@uhn.ca",
        "first_name": "Lillian",
        "institution_name": "Princess Margaret Cancer Centre",
        "last_name": "Siu",
        "staff_role": "Overall Principal Investigator"
      }
    ]
  },
  "status": "Open to Accrual",
  "treatment_list": {
    "step": [
      {
        "arm": [
          {
            "arm_code": "Group 1",
            "arm_description": "Experimental: Group 1",
            "arm_internal_id": 1,
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "Axitinib",
                "level_description": "5mg orally twice daily",
                "level_internal_id": 1,
                "level_suspended": "N"
              }
            ],
            "match": [
              {
                "and": [
                  {
                    "or": [
                      {
                        "genomic": {
                          "cnv_call": "High level amplification",
                          "hugo_symbol": "FLT1",
                          "variant_category": "Copy Number Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "FLT1",
                          "variant_category": "Mutation"
                        }
                      },
                      {
                        "genomic": {
                          "cnv_call": "High level amplification",
                          "hugo_symbol": "KDR",
                          "variant_category": "Copy Number Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "KDR",
                          "variant_category": "Mutation"
                        }
                      },
                      {
                        "genomic": {
                          "cnv_call": "High level amplification",
                          "hugo_symbol": "FLT4",
                          "variant_category": "Copy Number Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "FLT4",
                          "variant_category": "Mutation"
                        }
                      }
                    ]
                  },
                  {
                    "clinical": {
                      "age_numerical": ">=18",
                      "oncotree_primary_diagnosis": "!Renal Cell Carcinoma"
                    }
                  }
                ]
              }
            ]
          },
          {
            "arm_code": "Group 2",
            "arm_description": "Experimental: Group 2",
            "arm_internal_id": 2,
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "Bosutinib",
                "level_description": "500mg orally once daily",
                "level_internal_id": 2,
                "level_suspended": "N"
              }
            ],
            "match": [
              {
                "and": [
                  {
                    "or": [
                      {
                        "genomic": {
                          "display_name": "BCR-ABL1",
                          "fusion_partner_hugo_symbol": "ABL1",
                          "hugo_symbol": "BCR",
                          "molecular_function": "Activating",
                          "variant_category": "Structural Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "SRC",
                          "molecular_function": "Activating",
                          "variant_category": "Mutation"
                        }
                      }
                    ]
                  },
                  {
                    "clinical": {
                      "age_numerical": ">=18",
                      "oncotree_primary_diagnosis": "!Chronic Myelogenous Leukemia"
                    }
                  }
                ]
              }
            ]
          },
          {
            "arm_code": "Group 3",
            "arm_description": "Experimental: Group 3",
            "arm_internal_id": 3,
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "Crizotinib",
                "level_description": "250mg orally twice daily",
                "level_internal_id": 3,
                "level_suspended": "N"
              }
            ],
            "match": [
              {
                "and": [
                  {
                    "or": [
                      {
                        "genomic": {
                          "hugo_symbol": "ALK",
                          "variant_category": "Structural Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "ROS1",
                          "variant_category": "Mutation",
                          "molecular_function": "Activating"
                        }
                      },
                      {
                        "genomic": {
                          "cnv_call": "High Amplication",
                          "hugo_symbol": "MET",
                          "variant_category": "Copy Number Variation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "MET",
                          "variant_category": "Mutation",
                          "molecular_function": "Activating"
                        }
                      }
                    ]
                  },
                  {
                    "clinical": {
                      "age_numerical": ">=18",
                      "oncotree_primary_diagnosis": "!Non-Small Cell Lung Cancer"
                    }
                  }
                ]
              }
            ]
          },
          {
            "arm_code": "Group 4",
            "arm_description": "Experimental: Group 4",
            "arm_internal_id": 4,
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "Dasatinib",
                "level_description": "100mg administered orally once daily",
                "level_internal_id": 4,
                "level_suspended": "N"
              }
            ],
            "match": [
              {
                "and": [
                  {
                    "or": [
                      {
                        "genomic": {
                          "hugo_symbol": "KIT",
                          "molecular_function": "Activating",
                          "variant_category": "Mutation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "PDGFRA",
                          "molecular_function": "Activating",
                          "variant_category": "Mutation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "PDGFRB",
                          "molecular_function": "Activating",
                          "variant_category": "Mutation"
                        }
                      },
                      {
                        "genomic": {
                          "hugo_symbol": "ABL1",
                          "molecular_function": "Activating",
                          "variant_category": "Mutation"
                        }
                      }
                    ]
                  },
                  {
                    "and": [
                      {
                        "clinical": {
                          "age_numerical": ">=18",
                          "oncotree_primary_diagnosis": "!Chronic Myelogenous Leukemia"
                        }
                      },
                      {
                        "clinical": {
                          "age_numerical": ">=18",
                          "oncotree_primary_diagnosis": "!Gastrointestinal Stromal Tumor"
                        }
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "arm_code": "Group 5",
            "arm_description": "Experimental: Group 5",
            "arm_internal_id": 5,
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "Erlotinib",
                "level_description": "150mg orally, once daily",
                "level_internal_id": 5,
                "level_suspended": "N"
              }
            ],
            "match": [
              {
                "and": [
                  {
                    "genomic": {
                      "hugo_symbol": "EGFR",
                      "molecular_function": "Activating",
                      "variant_category": "Mutation"
                    }
                  },
                  {
                    "clinical": {
                      "age_numerical": ">=18",
                      "oncotree_primary_diagnosis": "!Non-Small Cell Lung Cancer"
                    }
                  }
                ]
              }
            ]
          },
                  ]
      }
    ]
  }
}
